A multicenter, Phase 3, randomized, open label, active-controlled, parallel-group trial investigating the safety, tolerability and efficacy of Transcon hGH administration once-a-week versus standard daily hGH replacement therapy over 52 weeks in pre-pube
|Effective start/end date||9/1/16 → 9/30/21|
- ASCENDIS PHARMA, INC.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.